T. lt； P gt； this disclosure； oacute； n refers to the agent of iarn, such as the double chain agent of iarn, which can inhibit the expression of amp； oacete； n-type angiographic gene 3 (tambi amp； eacute； n-type ANGPTL3, angpl3, prote amp； Iacute； Na angopoietine type 3),Agent Ilan, including ampter L3 Tambi amp； eacute； n publishes M amp； eacute； all for the agency and composition of iarn ANGPTL3. Currently disclosed iarn ANGPTL3 agents can be combined with targeted alliances to promote administration； oacute； N-C amp； eacute； Lulas, including liver. Tambi amp； eacute； n describes the pharmacology and amp； amp； amp； amp； amp； amp； amp； amp； amp； TL3 agents for Aacute； iarn,Select one or one of the M amp； Aacute； s treatment and additional uses of the amp； eacute. Administration agency CI amp； oacute； iarn provides inhibitors on site； oacete； n de la expui amp； oacute； n de Gen ANGPTL3, which may lead to lower triglyceride and amp； eacute； ridis and / or cholesterol levels of subjects. Iarn's agent can be used in M amp； eacute； for all ANGPTL3 related diseases and diseases, including cardiovascular diseases such as hyperglycemia and hyperlipidemia； P gt；<；p>；LA PRESENTE DIVULGACIÓ；N SE REFIERE A AGENTES DE IARN, POR EJEMPLO, AGENTES DE IARN DE CADENA DOBLE, CAPACES DE INHIBIR LA EXPRESIÓ；N DEL GEN DE LA ANGIOPOYETINA TIPO 3 (TAMBIÉ；N DENOMINADA ANGPTL3, ANGPL3, PROTEÍ；NA ANGIOPOYETINA TIPO 3), Y COMPOSICIONES QUE INCLUYEN AGENTES DE IARN DE ANGPTL3. TAMBIÉ；N SE DIVULGAN MÉ；TODOS PARA USAR LOS AGENTES DE IARN DE ANGPTL3 Y COMPOSICIONES. LOS AGENTES DE IARN DE ANGPTL3 DIVULGADOS EN LA PRESENTE PUEDEN ESTAR CONJUGADOS CON LIGANDOS DE DIRECCIONAMIENTO PARA FACILITAR LA ADMINISTRACIÓ；N A CÉ；LULAS, INCLUSIVE A HEPATOCITOS. TAMBIÉ；N SE DESCRIBEN COMPOSICIONES FARMACÉ；UTICAS QUE INCLUYEN UNO O MÁ；S AGENTES DE IARN DE ANGPTL3, OPCIONALMENTE CON UNO O MÁ；S PRODUCTOS TERAPÉ；UTICOS AD
